Pharmacogenomic eQTL mediated by androgen receptor modulators

Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor  (ER). The androgen receptor (AR) is also expressed in the vast majority (80-90%) of ER-positive tumors. However, AR-targeting drugs are not used in clinical practice, but have been evaluated in multiple trials and preclinical studies. We performed a genome-wide study to identify genetic context-dependent AR signaling induced by either AR agonist (dihydrotestosterone [DHT]), or AR antagonist (enzalutamide [Enz]), known as pharmacogenomic expression quantitative expression loci (PGx-eQTLs), utilizing a previously well characterized lymphoblastic cell line panel. 30 LCL panel were treated with DHT, enzalutamide, their combination, or Veh, and subjected to RNAseq